Jun 2026 (Q3 FY26) — Aug 10, 2026
Veru Q3 FY26 — Enobosarm Patent Allowance and PLATEAU Study Enrollment Complete
Read the full callVeru (VERU) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
Veru earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -7.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.31 +0.43% · +$0.01
Performance −43.8% 1Y
1Y: $4.11 on 17 Oct 2025 → $2.31. High $4.43 (20 Oct 2025), low $2.09 (27 Mar 2026).
- Previous close
- $2.3
- 52-week range
- $2.09 – $4.43
- One year
- −47.86%
Overview
- Symbol
- VERU
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Veru earnings calls (VERU)
Financials
What the filings say
Net profit, year on year: +5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | — | 0 | 0 | — | — | — | — |
| Operating profit | -8 | -10 | -8 | -8 | 1 | -5 | -7 | -8 |
| Operating margin | −123.3% | — | — | — | — | — | — | — |
| Other income | 0 | 8 | 0 | 0 | 0 | 0 | 4 | 1 |
| Interest | 0 | — | — | — | — | — | — | — |
| Net profit | -9 | -9 | -8 | -7 | 1 | -5 | -3 | -7 |
| EPS ($ per share) | — | -0.61 | -0.54 | -0.50 | — | -0.26 | -0.12 | -0.30 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Reserves | -58 | -70 | -89 | -82 | -164 | -257 | -295 | -317 |
| Total liabilities | 19 | 21 | 21 | 26 | 53 | 30 | 28 | 12 |
| Fixed assets | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 |
| Total assets | 48 | 54 | 52 | 178 | 135 | 50 | 60 | 30 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | -5 | -2 | -16 | -48 | -88 | -22 | -30 |
| Cash from investing | -0 | -0 | -0 | 15 | 4 | 6 | 0 | 25 |
| Cash from financing | 12 | 8 | 9 | 110 | 1 | 11 | 37 | -4 |
| Net cash flow | 0 | 3 | 7 | 109 | -42 | -71 | 15 | -9 |
| Capital expenditure | -0 | -0 | -0 | -0 | -1 | -1 | -0 | -0 |
| Free cash flow | -12 | -6 | -2 | -16 | -48 | -89 | -22 | -30 |
Insider filings
1 filing, all on Aug 13, 2026.
Open market
decisions to buy or sellPurchases
$4.8K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BARNETTE K GARY | $4.8K | — | Aug 13, 2026 |
Latest filings (3)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | BARNETTE K GARY Chief Scientific Officer | Purchase | 1,800 | $4.8K |
| Feb 19, 2025 | Rankowitz Michael L Director | Purchase | 54,721 | $31.9K |
| Feb 18, 2025 | Rankowitz Michael L Director | Purchase | 95,279 | $52.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for VERU INC.
Free account. Everything above stays public.
Write why you follow VERU INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading